Additional work has demonstrated that metformin can also suppress epigenetic modifier, enhancer of zeste homolog 2 (EZH2), in its anti-cancer activity in prostate adenocarcinoma and neuroendocrine tumors [161,162]. This evidence concerns the gene EZH2 and prostate adenocarcinoma.